JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

ABT

134.76

+1.17%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

ABT

134.76

+1.17%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

ABT

134.76

+1.17%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

ABT

134.76

+1.17%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

ABT

134.76

+1.17%↑

Search

Eli Lilly and Co.

Suletud

SektorTervishoid

757.36 3.2

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

732.88

Max

758.64

Põhinäitajad

By Trading Economics

Sissetulek

-6.1B

2.8B

Müük

-804M

13B

P/E

Sektori keskmine

61.579

56.602

Aktsiakasum

3.34

Dividenditootlus

0.82

Kasumimarginaal

21.678

Töötajad

47,000

EBITDA

-2B

4.2B

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+37.39% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

0.82%

2.45%

Järgmine tulemuste avaldamine

6. aug 2025

Järgmine dividendimakse kuupäev

10. juuni 2025

Järgmine aktsia dividendi kuupäev (ex-date)

16. mai 2025

Turustatistika

By TradingEconomics

Turukapital

-149B

678B

Eelmine avamishind

754.16

Eelmine sulgemishind

757.36

Uudiste sentiment

By Acuity

63%

37%

335 / 382 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

Eli Lilly and Co. Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

1. mai 2025, 11:24 UTC

Tulu

Eli Lilly 1Q Revenue Surges on Demand for Mounjaro, Other Weight-Loss Treatments

22. apr 2025, 09:26 UTC

Suurimad hinnamuutused turgudel

Novo Nordisk Shares Fall After Data From New Eli Lilly Pill

18. apr 2025, 15:57 UTC

Suurimad hinnamuutused turgudel

Eli Lilly CEO Ricks Warns Against Unintentionally Raising Prices as Weight-Loss Pill Nears Market Launch

12. mai 2025, 22:14 UTC

Peamised uudised

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12. mai 2025, 18:45 UTC

Peamised uudised

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

12. mai 2025, 17:14 UTC

Peamised uudised

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- WSJ

7. mai 2025, 17:01 UTC

Peamised uudised

Teva Will Hike Generic Drug Prices If Trump Imposes Tariffs, CEO Says -- Barrons.com

7. mai 2025, 13:56 UTC

Tulu

Novo Nordisk Stock Jumps After Earnings. Compounding Market's Growth Took it By Surprise -- Barrons.com

7. mai 2025, 11:18 UTC

Tulu

Novo Nordisk Stock Jumps After Earnings. It Cuts Guidance as Weight-Loss Drug Sales Slow. -- Barrons.com

7. mai 2025, 09:30 UTC

Peamised uudised

Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better. -- Heard on the Street -- WSJ

6. mai 2025, 20:30 UTC

Peamised uudised

Novo Nordisk Reports Earnings Soon. The Wegovy Manufacturer Is Scrambling to Hold Market Share. -- Barrons.com

4. mai 2025, 04:05 UTC

Omandamised, ülevõtmised, äriostud

UnitedHealth's Stock Is Ailing. A Bigger Business Hasn't Helped. -- Barrons.com

1. mai 2025, 21:07 UTC

Market Talk

Weight-Loss Drug Competitive Pressures Hammer Eli Lilly Shares -- Market Talk

1. mai 2025, 14:07 UTC

Tulu

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

1. mai 2025, 12:47 UTC

Tulu

These Stocks Are Moving the Most Today: Microsoft, Meta, Tesla, Apple, CVS, Eli Lilly, McDonald's, Moderna, and More -- Barrons.com

1. mai 2025, 12:00 UTC

Peamised uudised

Lower Taxes Could Bring More Drug Production to U.S., Says Eli Lilly CEO -- WSJ

1. mai 2025, 11:58 UTC

Tulu

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

1. mai 2025, 11:06 UTC

Tulu

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

1. mai 2025, 10:48 UTC

Tulu

Eli Lilly Earnings Beat Expectations. The Stock Is Falling. -- Barrons.com

1. mai 2025, 10:48 UTC

Tulu

Eli Lilly Sees FY Rev $58.0B-$61.0B >LLY

1. mai 2025, 10:45 UTC

Tulu

Eli Lilly 1Q Adj EPS $3.34 >LLY

1. mai 2025, 10:45 UTC

Tulu

Eli Lilly Sees FY EPS $20.17-EPS $21.67 >LLY

1. mai 2025, 10:45 UTC

Tulu

Eli Lilly 1Q Net $2.76B >LLY

1. mai 2025, 10:45 UTC

Tulu

Eli Lilly 1Q Rev $12.73B >LLY

1. mai 2025, 10:45 UTC

Tulu

Eli Lilly 1Q EPS $3.06 >LLY

1. mai 2025, 10:45 UTC

Tulu

Eli Lilly Sees FY Adj EPS $20.78-Adj EPS $22.28 >LLY

30. apr 2025, 09:30 UTC

Peamised uudised

Why New Wegovy Deals Won't Restore Novo's Obesity Lead -- Heard on the Street -- WSJ

28. apr 2025, 13:58 UTC

Peamised uudised

IBM, Apple, Eli Lilly: Tracking Corporate Spending Pledges Under Trump -- WSJ

22. apr 2025, 09:31 UTC

Kuumad aktsiad

Stocks to Watch Tuesday: Tesla, Novo Nordisk, Hertz -- WSJ

17. apr 2025, 18:27 UTC

Peamised uudised

Lilly's First Pill for Diabetes, Weight Loss Shows Positive Study Results -- Update

Võrdlus sarnastega

Hinnamuutus

Eli Lilly and Co. Prognoos

Hinnasiht

By TipRanks

37.39% tõus

12 kuu keskmine prognoos

Keskmine 983.13 USD  37.39%

Kõrge 1,124 USD

Madal 700 USD

Põhineb 20 Wall Streeti analüütiku instrumendi Eli Lilly and Co. 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

20 ratings

18

Osta

1

Hoia

1

Müü

Tehniline skoor

By Trading Central

N/A / 884.54Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

Strong Bearish Evidence

Sentiment

By Acuity

335 / 382 Pingereas Tervishoid

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.